1. 2904 Patterns of response and relapse of primary central nervous system lymphomas (PCNSL) following first line of high-dose methotrexate-based chemotherapy (hdMTX): Independent review of a prospective ANOCEF randomized phase II trial. (September 2015) Authors: Tabouret, E.; Houillier, C.; Martin-Duverneuil, N.; Blonski, M.; Soussain, C.; Ghesquieres, H.; Houot, R.; Delwail, V.; Soubeyran, P.; Gressin, R.; Gyan, E.; Lemercier, S.; Chinot, O.; Taillandier, L.; Tanguy, M.L.; Antonio, O.; Hoang-Xuan, K. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S586 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CLINICO‐BIOLOGICAL CHARACTERISTICS AND TREATMENT OUTCOMES FOR AGRESSIVE MANTLE CELL LYMPHOMA PATIENTS INCLUDED IN CLINICAL TRIALS. A LYSA STUDY. (12th June 2019) Authors: Baldacini, M.; Burroni, B.; Le Gouill, S.; Gressin, R.; Hermine, O.; Traverse‐glehen, A.; Martin, A.; Moreau, A.; Bene, M.; Fogarty, P.; Canioni, D.; Fornecker, L. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 237 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY. (12th June 2019) Authors: Ferrero, S.; Ladetto, M.; Beldjord, K.; Drandi, D.; Stelitano, C.; Bernard, S.; Castagnari, B.; Bouabdallah, K.; Cesaretti, M.; Alvarez, I.; Gressin, R.; Ponzoni, M.; Tripodo, C.; Traverse‐Glehen, A.; Baseggio, L.; Liberati, A.; Merli, M.; Tessoulin, B.; Patti, C.; Cabras, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 224 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL. (June 2017) Authors: Gressin, R.; Daguindau, N.; Tempescul, A.; Moreau, A.; Carras, S.; Cartron, G.; Schmitt, A.; Houot, R.; Dartigeas, C.; Pignon, J.; Corm, S.; Bannos, A.; Mounier, C.; Dupuis, J.; Macro, M.; Fleury, J.; Jardin, F.; Karlin, L.; Damaj, G.; Feugier, P. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. IBRUTINIB IN RELAPSE OR REFRACTORY PRIMARY CNS AND VITREO‐RETINAL LYMPHOMA. RESULTS OF THE PRIMARY END‐POINT OF THE ILOC PHASE II STUDY FROM THE LYSA AND THE FRENCH LOC NETWORK. (June 2017) Authors: Soussain, C.; Choquet, S.; Houillier, C.; Bijou, F.; Houot, R.; Boyle, E.; Gressin, R.; Nicolas‐Virelizier, E.; Barrie, M.; Moluçon‐Chabrot, C.; Lelez, M.; Clavert, A.; Coisy, S.; de la Bretonnière, M. Ertault; El Yamani, A.; Touitou, V.; Cassoux, N.; Boussetta, S.; Broussais, F.; Gelas‐Dore, B. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. (August 2019) Authors: Soussain, C.; Choquet, S.; Blonski, M.; Leclercq, D.; Houillier, C.; Rezai, K.; Bijou, F.; Houot, R.; Boyle, E.; Gressin, R.; Nicolas-Virelizier, E.; Barrie, M.; Moluçon-Chabrot, C.; Lelez, M.L.; Clavert, A.; Coisy, S.; Leruez, S.; Touitou, V.; Cassoux, N.; Daniau, M. Journal: European journal of cancer Issue: Volume 117(2019) Page Start: 121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P1133: SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT RITUXIMAB MAINTENANCE IMPROVES PFS IN PATIENTS WITH LOW-TUMOR BURDEN FOLLICULAR LYMPHOMA. FINAL RESULTS OF FLIRT PHASE III TRIAL, A LYSA STUDY. (23rd June 2022) Authors: Cartron, G.; Bachy, E.; Tilly, H.; Daguindau, N.; Pica, G.-M.; Bijou, F.; Mounier, C.; Clavert, A. M.; Damaj, G. L.; Slama, B.; Casasnovas, O.; Houot, R.; Bouabdallah, K.; Sibon, D.; Fitoussi, O.; Morineau, N.; Herbaux, C.; Gastinne, T.; Fornecker, L.-M.; Haioun, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1023 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P1186: A LARGE FRENCH REAL WORLD MULTICENTRIC PROSPECTIVE COHORT OF PATIENTS WITH LYMPHOMA (REALYSA STUDY): DESCRIPTION OF THE DIFFUSE LARGE B CELL LYMPHOMA PATIENTS IN REAL WORLD IN FRANCE. (23rd June 2022) Authors: Ghesquieres, H.; Cherblanc, F.; Belot, A.; Camus, V.; Thokagevistk, K.; Bouabdallah, K.-K.; Esnault, C.; Fornecker, L.-M.; Micon, S.; Bijou, F.; Haioun, C.; Morineau, N.; Ysebaert, L.; Damaj, G.; Le Gouill, S.; Guidez, S.; Morschhauser, F.; Thiéblemont, C.; Chauchet, A.; Gressin, R. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1072 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PHASE 2 STUDY OF PARSACLISIB (INCB050465) FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) (CITADEL‐202). (12th June 2019) Authors: Belada, D.; Fay, K.; Casasnovas, R.; Gressin, R.; Lee, H.; Mehta, A.; Munoz, J.; Verhoef, G.; Corrado, C.; DeMarini, D.; Zhao, W.; Chen, X.; Coleman, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 326 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38). (17th June 2021) Authors: Pirosa, M. C.; Orsucci, L.; Feugier, P.; Tani, M.; Ghesquieres, Hervé; Musuraca, G.; Baldini, L.; Merli, F.; De Renzis, B.; Gyan, E.; Gini, G.; Marino, D.; Gressin, R.; Morschhauser, F.; Palombi, F.; Cavallo, F.; Conconi, A.; Le Gouill, S.; Tilly, Hervé; Zanni, M. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗